Company profile: EMulate Therapeutics
1.1 - Company Overview
Company description
- Provider of clinical-stage therapeutic devices using proprietary ultra-low radio frequency energy (ulRFE) to elicit therapeutic biological effects. Programs include clinical testing in brain cancer and preclinical work in pain and mental health, advanced by subsidiaries: Cellsana (oncology; Phase III prep for glioblastoma/diffuse midline glioma), Mensana (mental health; Phase I prep), and Indolor (pain; Phase I prep).
Products and services
- Cellsana Therapeutics: Phase III–ready oncology subsidiary architecting trials for glioblastoma and diffuse midline glioma, with potential application across various solid tumors
- Mensana Therapeutics: Phase I–ready mental-health subsidiary applying psychoactive ulRFE fields to prepare trials for PTSD, depression, anxiety, and addiction
- UlRFE Technology: Proprietary platform using ultra-low radio frequency energy to produce therapeutic biological effects
- Undergoing clinical testing in brain cancer and preclinical testing for pain and mental health disorders
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to EMulate Therapeutics
KisoJi Biotechnology
HQ: Canada
Website
- Description: Provider of biotechnology solutions for healthcare and life sciences R&D, offering KisoMouse, a transgenic mouse platform for single-domain antibodies; KisoSeek, an NGS- and AI-guided structural antibody screening tool; KisoBody, a multi-functional, multi-specific antibody format; and therapeutic candidates including KJ-103 (TROP2, IND-enabling, solid tumors), KJ-101 (PD1/CD47/D2, IND-enabling), and KJ-102 (PD1/CD47/CD36, research, AML).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full KisoJi Biotechnology company profile →
BioVex
HQ: United Kingdom
Website
- Description: Provider of biological treatments for cancer and infectious diseases, focused on development and commercialization. Its cancer program includes OncoVEXGM-CSF, an oncolytic vaccine/cancer-destroying virus that replicates and spreads within solid tumors, causing tumor destruction, and it advances biological treatments for the prevention of infectious disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioVex company profile →
Precipio
HQ: United States
Website
- Description: Provider of cancer diagnostics and personalized medicine, offering hematopathology clinical diagnostic services and SmartPath second-opinion services for treatment plan validation, molecular testing reagents including HemeScreen, Bloodhound BCR-ABL1, and HemeScreen AML, and IV-Cell culture media for multi-cell lineage with simplified workflow and clinical accuracy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Precipio company profile →
Zymeworks
HQ: Canada
Website
- Description: Provider of computational biotechnology for optimizing therapeutic antibodies and other protein-based therapeutics, with a pipeline of bispecific antibodies and antibody-drug conjugates targeting HER2, folate receptor-α, mesothelin, glypican-3, and NaPi2b, including zanidatamab, zanidatamab zovodotin, ZW191, ZW171, ZW251, and ZW220.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zymeworks company profile →
Auron Therapeutics
HQ: United States
Website
- Description: Provider of cancer therapeutics focused on transforming malignant cells toward more normal function. Offerings include AURIGIN, an AI/ML platform to identify and target drivers of tumor cell plasticity and altered cellular states in cancer, and AUTX-703, an orally available small molecule therapy targeting KAT2A/B for small cell lung cancer, neuroendocrine prostate cancer, and acute myeloid leukemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Auron Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for EMulate Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to EMulate Therapeutics
2.2 - Growth funds investing in similar companies to EMulate Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for EMulate Therapeutics
4.2 - Public trading comparable groups for EMulate Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →